Genexine Inc
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses… Read more
Genexine Inc (095700) - Total Liabilities
Latest total liabilities as of September 2025: ₩106.21 Billion KRW
Based on the latest financial reports, Genexine Inc (095700) has total liabilities worth ₩106.21 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genexine Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how Genexine Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genexine Inc Competitors by Total Liabilities
The table below lists competitors of Genexine Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bank Bukopin Tbk
JK:BBKP
|
Indonesia | Rp81.06 Trillion |
|
Wendell Industrial Co. Ltd
TWO:6761
|
Taiwan | NT$867.74 Million |
|
Eugene Corporation
KQ:023410
|
Korea | ₩1.39 Trillion |
|
Chinese Maritime Transport Ltd
TW:2612
|
Taiwan | NT$12.56 Billion |
|
G8 Education Ltd
AU:GEM
|
Australia | AU$1.00 Billion |
|
Loncor Resources Inc
TO:LN
|
Canada | CA$1.78 Million |
|
Shining Building Business Co Ltd
TW:5531
|
Taiwan | NT$32.96 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Genexine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genexine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genexine Inc (2009–2024)
The table below shows the annual total liabilities of Genexine Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩83.36 Billion | +4.62% |
| 2023-12-31 | ₩79.68 Billion | -29.25% |
| 2022-12-31 | ₩112.63 Billion | -5.45% |
| 2021-12-31 | ₩119.12 Billion | +94.32% |
| 2020-12-31 | ₩61.30 Billion | +0.06% |
| 2019-12-31 | ₩61.27 Billion | +12.82% |
| 2018-12-31 | ₩54.30 Billion | +102.44% |
| 2017-12-31 | ₩26.83 Billion | -5.77% |
| 2016-12-31 | ₩28.47 Billion | +74.28% |
| 2015-12-31 | ₩16.33 Billion | -6.94% |
| 2012-12-31 | ₩17.55 Billion | +15.89% |
| 2011-12-31 | ₩15.14 Billion | +34.71% |
| 2010-12-31 | ₩11.24 Billion | +162.52% |
| 2009-12-31 | ₩4.28 Billion | -- |